6 completed. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 1 | Completed 1 |
Follow Mimetogen Pharmaceuticals USA, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye 5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Syndromes, Dry Eye Disease | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 642 | 2023-06-28 | 2024-06-10 |
| Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Tavilermide ophthalmic solution, Placebo - Keratoconjunctivitis Sicca, Dry Eye | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 623 | 2019-03-28 | 2023-04-05 |
| A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution - Keratoconjunctivitis Sicca | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 400 | 2016-01-01 | 2019-08-16 |
| A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution - Keratoconjunctivitis Sicca | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 429 | 2015-12-01 | 2019-08-16 |
| A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye MIM-D3 Ophthalmic Solution, Vehicle - Dry Eye Syndromes | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 403 | 2013-10-01 | 2019-08-19 |
| Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye MIM-D3 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye | Phase 2 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 150 | 2010-11-01 | 2019-08-19 |
Dry Eye Syndromes (6) · Keratoconjunctivitis Sicca (3)
United States (6)
Garth Cumberlidge, PhD (3) · Gail Torkildsen, MD (1) · John Lonsdale, MD (1) · Karen Meerovitch, PhD (1)